MERCK & CO., INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 128.4 USD | +0.69% |
|
-0.71% | +17.68% |
| May. 02 | Merck: encouraging results in gastric cancer | CF |
| May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
Presentation Operator MessageOperator (Operator)Good morning. My name is Grace Lakra, and I'll...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
127.6
USD
Average target price
141.6
USD
Spread / Average Target
+11.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.68% | 323B | |
| +31.23% | 690B | |
| +26.01% | 546B | |
| -4.88% | 358B | |
| +5.50% | 287B | |
| +14.60% | 235B | |
| +5.51% | 199B | |
| -9.73% | 195B | |
| +4.68% | 161B | |
| -1.46% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc., Q1 2022 Earnings Call, Apr 28, 2022